Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B-cell lymphoma.

Adrien DanielDavid GhezCamille RavaiauDoriane CavalieriOlivier TournilhacCharles HerbauxMélanie RorizMathieu WemeauStéphanie GuilletJean Baptiste BossardDemarquette HélèneEleonore KaphanRegny CarolineLachenal FlorenceAdeline PieracheMarc MichelBertrand GodeauLouis Terriou

Published in: European journal of haematology (2022)

Ibrutinib in this setting provides good efficacy and safety profile. Clinical trials are needed to define subgroups of patients who will benefit from this strategy and establish its place in the therapeutic arsenal.

Keyphrases

clinical trial
chronic lymphocytic leukemia
diffuse large b cell lymphoma
randomized controlled trial
open label
drug induced
replacement therapy
smoking cessation
study protocol